Linking the Price of Cancer Drug Treatments to Their Clinical Value.

about

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.

P2860

Q30843820-769AC228-1ED3-4EF1-8D3B-895E9F407290 Q55252091-EEA94295-9C03-428C-8853-5D1E1DB3862F

P2860

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

Item

http://www.wikidata.org/entity/Q39787879

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@en

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@nl

type

Item

label

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@en

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@nl

prefLabel

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@en

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@nl

P1476

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

@en

P2093

Americo Cicchetti

http://www.w3.org/2001/XMLSchema#string

Filippo Drago

http://www.w3.org/2001/XMLSchema#string

Laura Longo

http://www.w3.org/2001/XMLSchema#string

Salvatore Salomone

http://www.w3.org/2001/XMLSchema#string

Silvana Mansueto

http://www.w3.org/2001/XMLSchema#string

Valentina Drago

http://www.w3.org/2001/XMLSchema#string

P2860

Bending the Cost Curve in Cancer Care

Abiraterone in metastatic prostate cancer without previous chemotherapy

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Abiraterone and increased survival in metastatic prostate cancer

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.

P304

579-589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-016-0403-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Navarria

Giacomo Pignataro

Lucia Gozzo

P577

2016-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27153824

http://www.w3.org/2001/XMLSchema#string

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

about

P2860

P2860

Linking the Price of Cancer Drug Treatments to Their Clinical Value.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698